Analysts at Zacks Investment Research upgraded shares of Ritter Pharmaceuticals Inc (NASDAQ: RTTR) from Sell to Hold today. With a rating of Hold on the stock, Ritter Pharmaceuticals Inc has a 52-week high of $3.13. The one-year price target of $5.33 is higher than the opening price of $1.37, that has caused a fair amount of other analysts to report on the company recently. Usually, after analysts publish an upgrade report on a stock, they will later issue periodic revisions, such as a price target change.
U.S. stocks closed higher Tuesday as investors anticipate the results of meetings from the Federal Reserve and the Bank of Japan.
The Dow Jones Industrial Average DJIA, +0.05% rose 9.79 points, or less than 0.1%, to close at 18,129.96.
The S&P 500 index SPX, +0.03% advanced 0.64 points to finish at 2,139.76, led by gains in the health-care and consumer-staples sectors.
The Nasdaq Composite index COMP, +0.12% gained 6.33 points, or 0.1%, to close at 5,241.35.
Yesterday Ritter Pharmaceuticals Inc (NASDAQ: RTTR) shares last traded at $1.45, which is a spike of $0.04 compared to the previous closing price. Opening at $1.37, they fluctuated from $1.35 and $1.47 throughout the day.
Ritter Pharmaceuticals Inc (NASDAQ: RTTR) now has a market cap of 12.45M.
83,556 shares traded hands yesterday, 110 percent higher than the average, out of a total float 4,427,000. Substantial increases in trading volume and price appreciation together could signal heavy volume accumulation by institutional investors.
As with all potential breakouts, investors watch for volume to be at least 40%-50% above normal on the breakout to indicate that fund managers and other professional investors are jumping in.
Institutional sponsorship is defined by ownership of a stock by mutual funds, banks, pension funds and other large institutions.
These professional investors have substantial teams of analysts that investigate thousands of stocks. Thus, watching their interests is a good way to make sure you are buying the right stocks.
Traders can make more useful decisions on trades when they track the trading habits of professional investors.
With that in mind, Ritter Pharmaceuticals Inc (NASDAQ: RTTR) now has a 50-day MA of $1.34 and 200-day MA of $1.49. It has traded in a 52-week range between $0.98 – 3.13 and today’s last price is 0.54% lower than the 52 week high of $3.13.
Earnings growth is an important factor to research when investing in stocks and investors seek companies that have raised their earnings at least 25% or more over a 3 year period.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.